Buy-and-Build · Kent + North London

The Kent Acquisition War Map

Not just when to buy — how to buy strategically: lead with the affluent private anchors, add cheap NHS feeders for density, and wire every spoke to funnel full-arch cases into your hubs on your own lab. Build a group that's bigger and nicer — and worth a higher multiple.

01 · The Thesis 5×-in, 10.5×-out

Buy independents at a blended ~5.4× EBITDA, lift each one +£100–140k EBITDA in 12 months (full-arch referral, NHS→private, lab + back-office synergy), then sell the whole platform at ~10.5×. Every £1 of acquired EBITDA is worth ~1.9× the day you buy it — before any growth.

🎯 Buy nice first

Lead each cluster with the affluent private anchor (Tunbridge Wells, Bromley, Deal, Cockfosters). It sets the brand, the margin and the full-arch funnel — then the cheap feeders bolt on around it.

🧲 Feeders for density

Add 4–6 NHS/mixed practices within 20–25 min of each hub. Cheap to buy, they own the local recall lists — so failing-dentition patients meet a GM brand before they Google "All-on-4 near me".

🏭 The lab is the moat

Route every full-arch case to the FTS hub on GM Dental Lab prosthetics (~£900–1,400 COGS vs £2,500–3,500 outsourced). You own the price floor no rival can match locally.

Why it makes the group "nicer", not just bigger: the mix shifts toward private, implant and full-arch income — lifting blended margin, brand prestige and recurring revenue. A premium, branded, full-arch-led regional platform re-rates at 10–11×; a random bag of NHS practices does not.

02 · The Strategic Buy Order

Sequence follows the logic: lock the home Medway turf → saturate the Bexleyheath full-arch hub → then the affluent mid-Kent towns → then the coast → North London last. You cannot do 10 deals a year well — a roll-up dies on integration, not sourcing.

Integration capacity is the real constraint: 2–3 deals/yr while you build the M&A + integration machine (2026–27), 4–5/yr at peak only after a minority-PE partner funds a dedicated integration team (2028–30), taper to 3–4 as you groom for exit (2031–32), and buy nothing in the exit year (2033) — a clean full year of audited numbers protects the multiple.

03 · The Clusters

Each cluster is a hub-and-spoke: one full-arch hub, a ring of feeder practices, and a single branded referral pathway funnelling the high-margin cases inward.

04 · Full Target List

Every target archetype with location, turnover, EBITDA, the multiple to pay and the price. Filter by cluster or role; click a column to sort. These are modelled archetypes anchored to real towns — confirm each against Companies House + broker accounts before approaching.

05 · Bigger and Nicer — the build

As the anchors come in, the group doesn't just grow — its quality rises: more private mix, higher blended margin, more full-arch flow, a defensible brand. That's what lifts the exit multiple from ~7× to ~10.5×.

Cumulative acquired EBITDA (£M)

At purchase (run-rate)After integration (+~60%)

The quality shift

"Nicer" = a higher share of private/implant/full-arch income, a recognised regional brand, recurring membership, and the only multi-site full-arch pathway in the county. Buyers pay up for exactly that.

06 · The Per-Practice Growth Playbook

The standardised 12-month machine that turns a bought-at-5×, ~£200k-EBITDA practice into a £300k+ one — six levers, full-arch first.

One full-arch case (GM-internal economics)

Patient price ~£13,800/arch (SE England £12–15.5k)
Prosthetic COGS in-house via GM Lab ~£900–1,400 vs £2,500–3,500 outsourced
Each acquired practice screened for failing-dentition / edentulous patients
Even 1–2 cases/month per practice = £42–90k of new EBITDA — ~45% of the whole uplift

£100k of new EBITDA bought at 5× and sold at 10.5× ≈ £1.05M of value created per practice — before any multiple expansion. Across 24–26 practices, that is the £100M-exit thesis.

07 · Density & Domination

Owning a market isn't "having practices there" — it's holding enough of the referral catchment that no rival can profitably market for a full-arch case. The moat is the lab + hub + academy triangle.

🏭 Lab

Own the prosthetics → own the price floor. No neighbouring independent can offer competitive full-arch pricing without a lab.

🏥 Hub

Concentrate the £13–16k/arch work in Bexleyheath (+ Ashford/Barnet satellites) — the one treatment corporates can't easily replicate.

🎓 Academy

Clinician supply — not capital — is the binding constraint (5,500+ unfilled NHS vacancies). The academy trains the placing surgeons the hubs need.

08 · Risks & Reality

The honest constraints on this program — so you buy with your eyes open.

Realistic range: a founder-led group building its M&A muscle should plan for ~16–22 well-integrated acquisitions by 2033, not 26 — the 26-target list is the pipeline you source from, with 4 already parked as reserve. The three things that most improve the odds: (1) stand up a dedicated integration team before deal #4; (2) take minority PE to fund peak-velocity years; (3) out-pay corporates only where the target is worth more inside your hub network than standalone — never in a bidding war on a practice that doesn't feed a hub.

Built from the GM Dental acquisition workflow (10 agents: 5 cluster market scans + sequencing, growth playbook, domination, reconciliation, red-team). Financials are modelled archetypes anchored to real Kent/London towns and 2026 market multiples (independents 5–7×, scale platforms 9–11×) — they are a sourcing framework, not verified target accounts. Diligence every practice individually.